Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women With LHRH Receptor Positive Gynecological Tumors.

Trial Profile

Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women With LHRH Receptor Positive Gynecological Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2014

At a glance

  • Drugs Zoptarelin doxorubicin (Primary)
  • Indications Endometrial cancer; Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 04 Feb 2014 Results have been published in the International Journal of Gynecological Cancer according to an AEterna Zentaris media release. Results were also reported in the media release.
    • 14 Sep 2011 Final results in patients with endometrial cancer were presented at the 17th International Meeting of the European Society of Gynaecological Oncology (ESGO).
    • 18 Jul 2011 Status changed from active, no longer recruiting to completed, according to information in an Aeterna Zentaris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top